Antagonists in poor-responder patients

Fertility and Sterility

Volumn 80, Issue SUPPL. 1, 2003, Pages

  Copperman, Alan B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Ganirelix; GnRH antagonist; Poor ovarian response; Treatment options

Indexed keywords

CETRORELIX; CLOMIFENE; ESTROGEN; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

CLINICAL TRIAL; CONFERENCE PAPER; DOWN REGULATION; DRUG EFFECT; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HORMONAL THERAPY; HUMAN; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; META ANALYSIS; MICRODOSIMETRY; ORAL CONTRACEPTION; OVARY; OVARY CYCLE; PREGNANCY RATE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0038721787     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)00765-9     Document Type: Conference Paper

References (34)

1. Ben-Rafael Z., Orvieto R., Feldberg D. The poor-responder patient in an in vitro fertilization-embryo transfer (IVF-ET) program. Gynecol Endocrinol. 8:1994;277-286.
2. Surrey E.R., Schoolcraft W.B. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 73:2000;667-676.
3. Kligman I, Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. 2001;76:1185-90.
4. Dor J., Seidman D.S., Ben-Shlomo I., Levran D., Karasik A., Mashiach S. The prognostic importance of the number of oocytes retrieved and estradiol levels in poor and normal responders in in vitro fertilization (IVF) treatment. J Assist Reprod Genet. 9:1992;228-232.
5. Toner J.P., Philput C.B., Jones G.S., Muasher S.J. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril. 55:1991;784-791.
6. Tanbo T., Dale P.O., Lunde O., Norman N., Abyholm T. Prediction of response to controlled ovarian hyperstimulation a comparison of basal and clomiphene citrate-stimulated follicle-stimulating hormone levels . Fertil Steril. 57:1992;819-824.
7. Seifer D.B., Lambert-Messerlian G., Hogan J.W., Gardiner A.C., Blazar A.S., Berk C.A. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril. 67:1997;110-114.
8. Matthews M., Hurst B., Papadakis M., Loeb T., Norton J., Mashburn P. Value of estradiol and progesterone levels before and after human chorionic gonadotropin administration in predicting in vitro fertilization success. Reprod Technol. 10:2001;302-306.
9. Jenkins J.M., Davies D.W., Devonport H., Anthony F.W., Gadd S.C., Watson R.H., et al. Comparison of "poor" responders with "good" responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization. Hum Reprod. 6:1991;918-921.
10. Galtier-Dereure F, De Bouard V, Picot MC, Vergnes C, Humeau C, Bringer J, et al. Ovarian reserve test with gonadotrophin-releasing hormone agonist buserlin: correlation with in-vitro fertilization outcome period. Hum Reprod 1996;11:1393-8.
11. Hofmann G.E., Toner J.P., Muasher S.J., Jones G.S. High-dose follicle-stimulating hormone (fsh) ovarian stimulation in low-responder patients for in vitro fertilization. J In Vitro Fert Embryo Tranf. 6:1989;285-289.
12. Fanchin R., de Ziegler D., Olivennes F., Taieb J., Dzik A., Frydman R. Exogenous follicle stimulating hormone ovarian reserve test (EFFORT) a simple and reliable screening test for detecting "poor responders" in in-vitro fertilization . Hum Reprod. 9:1994;. 1067-1011.
13. Muasher S.J. Controversies in assisted reproduction treatment of low responders . J Assist Reprod Genetics. 10:1993;112-114.
14. Navot D., Drews M.R., Bergh P.A., Guzman I., Karstaedt A., Scott R.T., et al. Age-related decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation. Fertil Steril. 61:1994;97-101.
15. Roest J., van Heusden A.M., Mous H., Zeilmaker G.H., Verhoeff A. The ovarian response as a predictor for successful in vitro fertilization treatment after the age of 40 years. Fertil Steril. 66:1996;969-973.
16. Syrop C.H., Willhoite A., Van Voorhis B.J. Ovarian volume a novel outcome predictor for assisted reproduction . Fertil Steril. 64:1995;1167-1171.
17. Pellicer A., Ardiles G., Neuspiller F., Remohi J., Simón C., Bonilla-Musoles F. Evaluation of the ovarian reserve in young low responders with normal basal levels of folllicle-stimulating hormone using three-dimensional ultrasonography. Fertil Steril. 70:1998;671-675.
18. Kupesic S., Jurjak A. Predictors of IVF outcome by three-dimensional ultrasound. Hum Reprod. 17:2002;950-955.
19. Bancsi L.F.J.M.M., Broekmans F.J.M., Eijkemans M.J.C., de Jong F.H., Habbema J.D.F., te Velde E.R. Predictors of poor ovarian response in in vitro fertilization a prospective study comparing basal markers of ovarian reserve . Fertil Steril. 77:2002;328-336.
20. Karande V.C., Jones G.S., Veeck L.L., Muasher S.J. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil Steril. 53:1990;486-489.
21. Land J.A., Yarmolinskaya M.I., Dumoulin J.C.M., Evers J.L.H. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril. 65:1996;961-965.
22. Stadtmauer L., Ditkoff E.C., Session D., Kelly A. High dosages of gonadotropins are associated with poor pregnancy outcomes after in vitro fertilization-embryo transfer. Fertil Steril. 61:1994;1058-1064.
23. Feldberg D., Farhi J., Ashkenazi J., Dicker D., Shalev J., Ben-Zion R. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril. 62:1994;343-346.
24. Scott R.T., Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril. 61:1994;880-885.
25. Schoolcraft W., Schlenker T., Gee M., Stevens J., Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril. 67:1997;93-97.
26. Akman M.A., Erden H.F., Tosun S.B., Bayazit N., Aksoy E., Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders results of a prospective randomized trial . Hum Reprod. 16:2001;868-870.
27. Fluker M., Grifo J., Leader A., Levy M., Meldrum D., Muasher S.J., et al. for the The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 75:2001;38-45.
28. Jones H.W., Acosta A.A., Andrews M.C., Garcia J.E., Jones G.S., Mayer J., et al. Three years of in vitro fertilization at Norfolk. Fertil Steril. 42:1984;826-834.
29. Meldrum D., Scott R., Levy M.J., Alper M., Noyes N. A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles. Fertil Steril. 78:(Suppl 1):2002;S176.
30. Shapiro D., Carter M., Mitchell-Leef D., Wininger D. Plateau or drop in estradiol (E2) on the day after initiation of the GnRH antagonist Antagon™ in in vitro fertilization (IVF) treatment cycles does not affect pregnancy outcome. Fertil Steril. 78:(Suppl 1):2002;S22.
31. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®). Hum Reprod. 13:1998;3023-3031.
32. Gordon K. Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity . Ann NY Acad Sci. 943:2001;49-54.
33. Chang P.L., Zeitoun K.M., Chan L.-K., Thornton M.H. II, Sauer M.V. GnRH antagonist in older IVF patients retrieval rates and clinical outcome . J Reprod Med. 47:2002;253-258.
34. Al-Inany H., Aboulghar M. GnRH antagonist in assisted reproduction a Cochrane review . Hum Reprod. 17:2002;874-885.